INS and type 2 diabetes mellitus: More direct studies documented that reducing β-cell output via insulin (glargine) supplementation or acute diazoxide treatment can improve β-cell responses and glycemic control [204,205,206]; however, concerns over hypoglycemic episodes and weight gain preclude the recommended use of basal insulin therapies as a single agent treatment for T2D [207].